首页> 外文期刊>Archives of Endocrinology and Metabolism >Preoperative detection of TERT promoter and BRAF V600E mutations in papillary thyroid carcinoma in high-risk thyroid nodules
【24h】

Preoperative detection of TERT promoter and BRAF V600E mutations in papillary thyroid carcinoma in high-risk thyroid nodules

机译:术前检测高危甲状腺结节中甲状腺乳头状癌的TERT启动子和BRAF V600E突变

获取原文
           

摘要

Objectives: This observational study analyzed telomerase reverse transcriptase ( pTERT ) mutations in 45 fine-needle aspiration (FNA) specimens obtained from thyroid nodules followed by postoperatively confirmation of papillary thyroid cancer (PTC) diagnosis, examining their relationship with clinicopathologic aspects and the BRAF V600E mutation. Subjects and methods: Clinical information was collected from patients who presented to Ribeirao Preto University Hospital for surgical consultation regarding a thyroid nodule and who underwent molecular testing between January 2010 to October 2012. Tests included a DNA-based somatic detection of BRAF V600E and pTERT mutations. Results: We found coexistence of pTERT C228T and BRAF V600E mutations in 8.9% (4/45) of thyroid nodules. All nodules positive for pTERT mutations were BRAF V600E positives. There was a significant association between pTERT C228T / BRAF V600E with older age and advanced stage compared with the group negative for either mutation. Conclusions: This series provides evidence that FNA is a reliable method for preoperative diagnosis of high-risk thyroid nodules. pTERT C228T / BRAF V600E mutations could be a marker of poor prognosis. Its use as a personalized molecular medicine tool to individualize treatment decisions and follow-up design needs to be further studied.
机译:目的:这项观察性研究分析了从甲状腺结节获得的45例细针穿刺(FNA)标本中的端粒酶逆转录酶(pTERT)突变,然后对乳头状甲状腺癌(PTC)的诊断进行了术后确认,并检查了它们与临床病理因素和BRAF V600E的关系突变。对象和方法:临床信息收集自就诊于甲状腺癌结节的Ribeirao Preto大学医院并在2010年1月至2012年10月间接受分子检测的患者。检测包括基于DNA的BRAF V600E和pTERT突变体细胞检测。结果:我们发现8.9%(4/45)甲状腺结节中存在pTERT C228T和BRAF V600E突变并存。 pTERT突变阳性的所有结节均为BRAF V600E阳性。与任一突变阴性组相比,pTERT C228T / BRAF V600E与年龄较大和晚期之间存在显着关联。结论:该系列提供证据证明FNA是术前诊断高危甲状腺结节的可靠方法。 pTERT C228T / BRAF V600E突变可能是预后不良的标志。它作为个性化分子医学工具来个性化治疗决策和后续设计的应用需要进一步研究。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号